Terns Pharmaceuticals Competitors

ImmunityBio (NASDAQ:IBRX) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.

Valuation and Earnings

This table compares ImmunityBio and Terns Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Profitability

This table compares ImmunityBio and Terns Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations and price targets for ImmunityBio and Terns Pharmaceuticals, as provided by MarketBeat.com.

ImmunityBio presently has a consensus target price of $25.00, suggesting a potential upside of 55.38%. Terns Pharmaceuticals has a consensus target price of $30.50, suggesting a potential upside of 71.93%. Given Terns Pharmaceuticals' higher possible upside, analysts plainly believe Terns Pharmaceuticals is more favorable than ImmunityBio.

Summary

Terns Pharmaceuticals beats ImmunityBio on 2 of the 2 factors compared between the two stocks.

BioAtla (NASDAQ:BCAB) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.

Valuation and Earnings

This table compares BioAtla and Terns Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Profitability

This table compares BioAtla and Terns Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations and price targets for BioAtla and Terns Pharmaceuticals, as provided by MarketBeat.com.

BioAtla presently has a consensus target price of $58.00, suggesting a potential upside of 20.26%. Terns Pharmaceuticals has a consensus target price of $30.50, suggesting a potential upside of 71.93%. Given Terns Pharmaceuticals' higher possible upside, analysts plainly believe Terns Pharmaceuticals is more favorable than BioAtla.

Terns Pharmaceuticals (NASDAQ:TERN) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability and institutional ownership.

Earnings and Valuation

This table compares Terns Pharmaceuticals and Immunocore's top-line revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Terns Pharmaceuticals and Immunocore's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Terns Pharmaceuticals and Immunocore, as reported by MarketBeat.

Terns Pharmaceuticals presently has a consensus price target of $30.50, suggesting a potential upside of 71.93%. Immunocore has a consensus price target of $54.3333, suggesting a potential upside of 68.63%. Given Terns Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Terns Pharmaceuticals is more favorable than Immunocore.

Summary

Terns Pharmaceuticals beats Immunocore on 3 of the 3 factors compared between the two stocks.

Terns Pharmaceuticals (NASDAQ:TERN) and Cricut (NASDAQ:EWTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability and institutional ownership.

Earnings and Valuation

This table compares Terns Pharmaceuticals and Cricut's top-line revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Terns Pharmaceuticals and Cricut's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Terns Pharmaceuticals and Cricut, as reported by MarketBeat.

Terns Pharmaceuticals presently has a consensus price target of $30.50, suggesting a potential upside of 71.93%. Given Terns Pharmaceuticals' higher possible upside, equities analysts clearly believe Terns Pharmaceuticals is more favorable than Cricut.

Summary

Terns Pharmaceuticals beats Cricut on 2 of the 2 factors compared between the two stocks.

Kinnate Biopharma (NASDAQ:KNTE) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Kinnate Biopharma and Terns Pharmaceuticals, as reported by MarketBeat.com.

Kinnate Biopharma presently has a consensus price target of $52.00, suggesting a potential upside of 73.39%. Terns Pharmaceuticals has a consensus price target of $30.50, suggesting a potential upside of 71.93%. Given Kinnate Biopharma's higher possible upside, equities research analysts clearly believe Kinnate Biopharma is more favorable than Terns Pharmaceuticals.

Valuation and Earnings

This table compares Kinnate Biopharma and Terns Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Kinnate Biopharma and Terns Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Kinnate Biopharma beats Terns Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

Cullinan Oncology (NASDAQ:CGEM) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.

Profitability

This table compares Cullinan Oncology and Terns Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Cullinan Oncology and Terns Pharmaceuticals, as reported by MarketBeat.com.

Cullinan Oncology presently has a consensus price target of $48.25, suggesting a potential upside of 61.53%. Terns Pharmaceuticals has a consensus price target of $30.50, suggesting a potential upside of 71.93%. Given Terns Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Terns Pharmaceuticals is more favorable than Cullinan Oncology.

Valuation and Earnings

This table compares Cullinan Oncology and Terns Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Summary

Terns Pharmaceuticals beats Cullinan Oncology on 2 of the 2 factors compared between the two stocks.